WA-KYMETA
15.11.2017 14:02:16 CET | Business Wire | Press release
Redmond-based Kymeta—the communications company making good on the promise of global mobile connectivity—set out on a two-week trek across America in its connected Toyota RAV4 to provide a rigorous, real-world proving ground for its widely anticipated KĀLO™ internet service. KĀLO services will deliver a new mobile satellite internet service that will make mobile high-throughput internet access available and easy to buy. The KĀLO Trek Across America will begin in Washington, D.C. and wind through the country, covering over 7,000 miles, and culminating in a homecoming event at the Kymeta campus in Washington state on November 27.
Powered by the IntelsatOne® Flex network, Kymeta KĀLO services will provide high-bandwidth mobile satellite internet access to industries that require connectivity on the move like military, news reporting, first responders, construction, trains, buses and more. KĀLO services, when paired with Kymeta™ KyWay™ terminals and mTennau7 ASMs, will connect places and fixed and mobile platforms that have traditionally had limited or no connectivity at all.
“Kymeta is taking its connected car across the country to put the network through the paces,” said Dushyant Sukhija, SVP and General Manager, KĀLO Business Unit, Kymeta. “When launched, KĀLO mobile internet services will mark a revolutionary change in the way satellite services are purchased and supplied, making it as simple as purchasing a cell phone plan. The launch of Kymeta KĀLO services will usher in changes in the way businesses get work done: on the move, from everyday vehicles, in even the most difficult to reach industries and areas of the world.”
The KĀLO Trek Across America tells another important story: the possibility of a truly connected car is now a reality. Kymeta’s Toyota RAV4 will remain connected throughout its U.S. journey, conducting live streams and updates from the road. “As innovations in satellite connectivity come to market, such as our Intelsat EpicNG high-throughput satellites, we are unlocking new applications. Industries recognize that connected cars and other vehicles will enable new services and opportunities for increased efficiency; traditional networks can’t support that growth today,” said Mark Rasmussen, VP and General Manager, Mobility, Intelsat. “Leveraging our global IntelsatOne Flex network, our partnership with Kymeta will bring KĀLO internet services to every corner of the U.S., and eventually every region of the world. This plan aligns to our goal: make connectivity accessible to everyone, everything, everywhere, at any time. Kymeta KĀLO services are proof that connectivity can reach every industry, large and small, and be used for any application, no matter where you are, especially while you’re on the move.”
For a map of the KĀLO Trek Across America destinations, and to follow along as the team gives updates on the route home, visit KĀLO Trek online .
About Kymeta
What’s the missing link to connecting billions of people to high-speed mobile access? Antennas. And Kymeta offers the world’s only commercially viable electronically scanning satellite antennas and terminals. Kymeta antennas and terminals deliver high-throughput communications for land, sea and air, making mobile connectivity as available as a view of the sky. Plus, the world’s largest satellite operator, Intelsat, has joined forces with Kymeta to deliver KĀLO™ global access services that combine with Kymeta antennas and terminals to provide revolutionary mobile connectivity. Without Kymeta mTenna™ technology, connecting and staying connected to all those new satellites while on the move will be difficult, if not impossible.
If it moves, Kymeta will keep it connected. Anywhere.
For more information, visit kymetacorp.com and KALO.net .
View source version on businesswire.com: http://www.businesswire.com/news/home/20171115005354/en/
Contact:
Business Inquiries for Kymeta:
Kymeta Corporation
Lisa
Dreher, +1 425-658-8724
Director of Marketing
ldreher@kymetacorp.com
or
Media
Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1
801-990-1185
Mobile: +1 801-783-9067
PR/Content Manager
aoliver@summitslc.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom